Lead Sponsor

Lexicon Pharmaceuticals

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Participant has given written informed consent to participate in the study in accordance with local regulations
•Adult male and female participants ≥18 years of age at the time of screening
•Body mass index ≥18.0 to ≤40.0 kg/m2 at Screening
•Diagnosis of diabetic peripheral neuropathic pain (DPNP) at Screening
•Pain from DPN present for at least 6 months
•Haemoglobin A1C ≤11% at screening
•Stable regimen for the treatment of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) for ≥1 month prior to Screening

•Presence of other painful conditions that may confound assessment or self-evaluation of DPNP
•History of major depressive episode, active, significant psychiatric disorders
•History of clinically significant drug or alcohol use disorder
•History of neurolytic or neurosurgical therapy for DPNP
•Use of opioid medications for management of DPNP within the 2 months prior to Screening Visit
•Use of non-steroidal anti-inflammatory drugs (NSAIDs) less than 2 weeks prior to the Screening Visit